Navigation Links
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
Date:12/5/2008

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, California.

Clinical investigators from leading oncology and hematology research centers will present data through several oral and poster presentations reporting important findings in leukemia-related disorders, such as prognostic indicators for chronic lymphocytic leukemia (CLL) and side effects such as chemotherapy-induced neutropenia.

Campath is indicated in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Leukine is indicated for use following induction chemotherapy in patients 55 years and older with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.

"We are pleased to see continued developments on both Campath and Leukine," said Pam Cyrus, Vice President, Medical Affairs, Oncology, Bayer HealthCare Pharmaceuticals. "These studies further demonstrate Bayer's ongoing commitment to supporting research to benefit the lives of people living with cancer."

Abstracts are now available on the ASH Web site at http://www.hematology.org.

Among the data that will be presented are the following:

Campath:

  • Poster 3164 (December 8, 5:30 p.m. PST) -- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study Within Various Cytogenetic Risk Categories

  • Poster 329 (December 8, 12:00 p.m
    '/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
2. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
3. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
6. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
9. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
10. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
11. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... 01, 2015 , ... Stress comes in many different forms ... changes can lead to very serious, life-altering events. Fortunately nature offers a range ... supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra ...
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... powers introduced by the government to enable specially trained ... been successfully adopted, according to a new report. ... Keele found widespread acceptance of the new powers among ... for the type of medical conditions being treated. ...
... HealthDay Reporter , MONDAY, May 9 (HealthDay News) -- ... nervous system disease known as amyotrophic lateral sclerosis (ALS), British ... does not mean people with long ring fingers will develop ... risk for it. "We have not done a study ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... link specific behaviors and health conditions to the onset of ... anything you do or don,t do will prevent the brain ... The U.S. National Institutes of Health convened a ...
... at Scripps Institution of Oceanography at UC San Diego ... known to produce substances potentially useful against human diseases. ... the oldest forms of life on the planet. At ... to humans and animals. But despite the recognized capability ...
... MONDAY, May 9 (HealthDay News) -- Could gastric bypass weight-loss ... That,s the finding from a group of Swedish researchers who ... the Digestive Disease Week conference in Chicago. A team ... patients who underwent primary bariatric surgery between 1980 and 2006. ...
... MONDAY, May 9 (HealthDay News) -- Overdiagnosis and overtreatment of ... to the large increase in the use of computed tomography ... embolism (PE) is a potentially life-threatening blood clot in the ... PE and its use has grown rapidly, according to background ...
Cached Medicine News:Health News:Wide-reaching report finds strong support for nurse and pharmacist prescribing 2Health News:Ring Finger Length Linked to ALS, Study Suggests 2Health News:Ring Finger Length Linked to ALS, Study Suggests 3Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 2Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 3Health News:Genome of marine organism reveals hidden secrets 2Health News:Genome of marine organism reveals hidden secrets 3Health News:Risk for Problem Drinking May Rise After Gastric Bypass 2Health News:Scan Technology Tied to Overtreatment of Clots in Lungs 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: